DOI QR코드

DOI QR Code

Prognostic Factors Influencing Clinical Outcomes of Malignant Glioblastoma Multiforme: Clinical, Immunophenotypic, and Fluorescence in Situ Hybridization Findings for 1p19q in 816 Chinese Cases

  • Qin, Jun-Jie (Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University) ;
  • Liu, Zhao-Xia (Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University) ;
  • Wang, Jun-Mei (Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University) ;
  • Du, Jiang (Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University) ;
  • Xu, Li (Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University) ;
  • Zeng, Chun (Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brain Tumor) ;
  • Han, Wu (Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brain Tumor) ;
  • Li, Zhi-Dong (Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brain Tumor) ;
  • Xie, Jian (Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brain Tumor) ;
  • Li, Gui-Lin (Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University)
  • Published : 2015.03.04

Abstract

Malignant glioblastoma multiforme (GBM) is the most malignant brain tumor and despite recent advances in diagnostics and treatment prognosis remains poor. In this retrospective study, we assessed the clinical and radiological parameters, as well as fluorescence in situ hybridization (FISH) of 1p19q deletion, in a series of cases. A total of 816 patients with GBM who received surgery and radiation between January 2010 and May 2014 were included in this study. Kaplan-Meier survival analysis and Cox regression analysis were used to find the factors independently influencing patient progression free survival (PFS) and overall survival (OS). Age at diagnosis, preoperative Karnofsky Performance Scale (KPS) score, KPS score change at 2 weeks after operation, neurological deficit symptoms, tumor resection extent, maximal tumor diameter, involvement of eloquent cortex or deep structure, involvement of brain lobe, Ki-67 and MMP9 expression level and adjuvant chemotherapy were statistically significant factors (p<0.05) for both PFS and OS in the univariate analysis. Cox proportional hazards modeling revealed that age ${\leq}50$ years, preoperative KPS score ${\geq}80$, KPS score change after operation ${\geq}0$, involvement of single frontal lobe, deep structure involvement, low Ki-67 and MMP9 expression and adjuvant chemotherapy were independent favorable factors (p<0.05) for patient clinical outcomes.

Keywords

Malignant glioblastoma multiform;prognostic factor;FISH of 1p19q;immunohistochemistry

Acknowledgement

Supported by : Beijing Institute for Brain Disorders

References

  1. Anda T, Shabani HK, Tsunoda K, et al (2003). Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res, 25, 241-8. https://doi.org/10.1179/016164103101201445
  2. Bredel M (2001). Anticancer drug resistance in primary human brain tumors. Brain Res Rev, 35, 161-204. https://doi.org/10.1016/S0165-0173(01)00045-5
  3. Chen SD, Song MM, Zhong ZQ et al (2012). Knockdown of radixin by RNA interference suppresses the growth of human pancreatic cancer cells in vitro and in vivo. Asian Pac J Cancer Prev, 13, 753-9. https://doi.org/10.7314/APJCP.2012.13.3.753
  4. Cheng CL, Johnson SP, Keir ST, et al (2005). Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther, 4, 1364-8. https://doi.org/10.1158/1535-7163.MCT-05-0128
  5. Darakhshan S, Bidmeshkipour A, Khazaei M, et al (2013). Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev, 14, 6869-74. https://doi.org/10.7314/APJCP.2013.14.11.6869
  6. Fazeny-Dorner B, Wenzel C, et al (2003). Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs, 14, 305-12. https://doi.org/10.1097/00001813-200304000-00008
  7. Fontaine D, Vandenbos F, et al (2008). Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice. Rev Neurol (Paris), 164, 595-604. https://doi.org/10.1016/j.neurol.2008.04.002
  8. Forsyth PA, Wong H, Laing TD, et al (1999). Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer, 79, 1828-35. https://doi.org/10.1038/sj.bjc.6990291
  9. Gorlia T, van den Bent MJ, Hegi ME, et al (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol, 9, 29-38. https://doi.org/10.1016/S1470-2045(07)70384-4
  10. Hoffman S, Propp JM, McCarthy BJ (2006). Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol, 8, 27-37. https://doi.org/10.1215/S1522851705000323
  11. Holden JA, Townsend JJ (1999). DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol, 12, 1094-100.
  12. Jadhav U, Chigurupati S, Lakka SS, Mohanam S (2004). Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol, 25, 1407-14.
  13. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J (2003). Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol, 129, 477-84. https://doi.org/10.1007/s00432-003-0471-5
  14. Jin J, Cai L, Liu ZM, et al (2013). miRNA-218 inhibits osteosarcoma cell migration and invasion by downregulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev, 14, 3681-4. https://doi.org/10.7314/APJCP.2013.14.6.3681
  15. Kang SG, Kim JH, Nam DH, Park K (2005). Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir, 45, 232-8; discussion 238-9. https://doi.org/10.2176/nmc.45.232
  16. Kidoikhammouan S, Seubwai W, Tantapotinan N, et al (2013). TNP-470, a methionine aminopeptidase-2 inhibitor, inhibits cell proliferation, migration and invasion of human cholangiocarcinoma cells in vitro. Asian Pac J Cancer Prev, 13, 155-60.
  17. Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE (2005). Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg, 103, 156-64. https://doi.org/10.3171/jns.2005.103.1.0156
  18. Kleihues P, Sobin LH (2000). World Health Organization classification of tumors. Cancer, 88, 2887. https://doi.org/10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F
  19. Lee SD (2008). Notice of retraction of “The experience with Ritleng intubation system in patients with congenital nasolacrimal duct obstruction”. 67, 344-8. J Chin Med Assoc, 71, 329. https://doi.org/10.1016/S1726-4901(08)70133-3
  20. Levicar N, Nuttall RK, Lah TT (2003). Proteases in brain tumour progression. Acta Neurochir (Wien), 145, 825-38. https://doi.org/10.1007/s00701-003-0097-z
  21. Li S, Jiang T, Wang Z (2008). Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res, 30, 567-70. https://doi.org/10.1179/174313208X297913
  22. Li SW, Qiu XG, Chen BS, et al (2009). Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J, 122, 1245-9.
  23. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
  24. Lutterbach J, Sauerbrei W, Guttenberger R (2003). Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol, 179, 8-15.
  25. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990). Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 8, 1277-80.
  26. Mineo JF, Bordron A, Baroncini M, et al (2007). Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir, 149, 245-52; discussion 252-43. https://doi.org/10.1007/s00701-006-1092-y
  27. Ng, SS, Cheung YT, An XM, et al (2007). Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma. J Natl Cancer Inst, 99, 936-48. https://doi.org/10.1093/jnci/djm011
  28. Park K, Kim J, Lim S, et al (2003).Topoisomerase II-alpha (topo II) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer, 39, 631-4. https://doi.org/10.1016/S0959-8049(02)00745-1
  29. Piroth MD, Gagel B, Pinkawa M, et al (2007). Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors. Strahlenther Onkol, 183, 695-702. https://doi.org/10.1007/s00066-007-1739-5
  30. Rao JS (2003). Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer, 3, 489-501. https://doi.org/10.1038/nrc1121
  31. Sabha N, Knobbe CB, Maganti M, et al (2014). Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol, 16, 914-923. https://doi.org/10.1093/neuonc/not299
  32. Saito T, Hama S, Kajiwara Y, et al (2006). Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas. Anticancer Res, 26, 1351-7.
  33. Sathornsumetee S, Rich JN (2006). New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther, 6, 1087-104. https://doi.org/10.1586/14737140.6.7.1087
  34. Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R (2010). Gliomas in adults. Dtsch Arztebl Int, 107, 799-807.
  35. Singh VY, Chacko G, Chacko AG, et al (2014). Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms. Neurol India, 62, 32-6. https://doi.org/10.4103/0028-3886.128275
  36. Smith JS, Jenkins RB (2000). Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci, 5, 213-31. https://doi.org/10.2741/Smith
  37. Smrdel U, Kovac V, Popovic M, Zwitter M (2014). Glioblastoma patients in Slovenia from 1997 to 2008. Radiol Oncol, 48, 72-9.
  38. Stojic J, Hagemann C, Haas S, et al (2008). Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Neurosci Res, 60, 40-9. https://doi.org/10.1016/j.neures.2007.09.009
  39. Stupp R, Hegi ME, van den Bent MJ, et al (2006). Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, 11, 165-80. https://doi.org/10.1634/theoncologist.11-2-165
  40. Stupp R, WP Mason, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96. https://doi.org/10.1056/NEJMoa043330
  41. Stupp R, Pavlidis N, Jelic S (2005). ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol, 16, 64-5. https://doi.org/10.1093/annonc/mdi024
  42. Stupp R, Weber DC (2005). The role of radio-and chemotherapy in glioblastoma. Onkologie, 28, 315-7. https://doi.org/10.1159/000085575
  43. Taniguchi K, Wakabayashi T, Yoshida T, et al (1999). Immunohistochemical staining of DNA topoisomerase II alpha in human gliomas. J Neurosurg, 91, 477-82. https://doi.org/10.3171/jns.1999.91.3.0477
  44. Tramacere F, Gianicolo E, Serinelli M, et al (2008). Multivariate analysis of prognostic factors and survival in patients with “glioblastoma multiforme. Clin Ter, 159, 233-8.
  45. VanMeter TE, Rooprai HK, Kibble MM, et al (2001). The role of matrix metalloproteinase genes in glioma invasion: codependent and interactive proteolysis. J Neurooncol, 53, 213-35. https://doi.org/10.1023/A:1012280925031
  46. Wen PY, Yung WK, Lamborn KR, et al (2006). Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res, 12, 4899-907. https://doi.org/10.1158/1078-0432.CCR-06-0773
  47. Yahayo W, Supabpho A, Supabphol R (2013). Suppression of human fibrosarcoma cell metastasis by Phyllanthus emblica extract in vitro. Asian Pac J Cancer Prev, 14, 6863-7. https://doi.org/10.7314/APJCP.2013.14.11.6863
  48. Yong VW (2005). Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci, 6, 931-44. https://doi.org/10.1038/nrn1807

Cited by

  1. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma pp.1523-5866, 2017, https://doi.org/10.1093/neuonc/nox193
  2. Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study pp.1573-7373, 2017, https://doi.org/10.1007/s11060-017-2726-z